DavidRSpriggsMDFASCO

Oncology • Boston, MA

Gynecologic Cancer, Hematologic Oncology

Professor in Residence

Join to view full profile

Dr. Spriggs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Spriggs' full profile

Already have an account?

Office
151 Tremont St
Apt26L
Boston, MA 02111

Summary

Consultant in early stage clinical development in immuno-oncology.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1982 - 1985
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1979 - 1982
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1977 - 1978
University of Wisconsin School of Medicine & Public HealthClass of 1977

Certifications & Licensure

Massachusetts, MA 1982 - 2026
NY State Medical License 1978 - 2022
ME State Medical License 2020 - 2021
WI State Medical License 1989 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow, American Society of Clinical Oncology American Society of Clinical Oncology, 2016
America's Top Doctors Castle Connolly, 2005-2016
Fellow, American College of Physicians American college of physicians, 2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2004-2008, 2010
Join now to see all

Clinical Trials

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer Start of enrollment: 2018 Dec 24
Recruiting
Phase 2

Publications & Presentations

PubMed

1 citations
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Yusuke Matoba, Dominique T Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim
British Journal of Cancer. 2024-05-01
3 citations
Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
Linah Al-Alem, Jillian M Prendergast, Justin Clark, Bianca Zarrella, Dominique T Zarrella
Journal of Ovarian Research. 2024-04-02
2 citations
Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Kwangkook Lee, Kay Perry, Mengyao Xu, Irva Veillard, Raj Kumar
Journal of Ovarian Research. 2024-02-19

Journal Articles

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
David Spriggs, MD, Clinical Cancer Research

Press Mentions

ASCO Reading Room | Working PARP Inhibitors Harder in Ovarian CaApril 2nd, 2019
Massachusetts Medical Society Announces Members of Search Committee for New England Journal of Medicine Editor-in-ChiefNovember 2nd, 2018
Shop TalkJune 25th, 2017
Join now to see all

Grant Support

Early Clinical Trials Of New Anti-Cancer Agents With Phase 1 EmphasisNational Cancer Institute2009–2012
Career Development ProgramNational Cancer Institute2010–2011
Clinical Investigator Development In Solid Tumor OncologyNational Cancer Institute2006–2010
Novel Strategy For The Re-Induction &Consolidation Of Remission In Ovary CancerNational Cancer Institute2007–2009
Epithelial Ovarian Cancer Program ProjectNational Cancer Institute2001–2009
Novel Strategy For Clinical Remission In Ovarian CancerNational Cancer Institute2005–2006
Cancer Chemotherapy Program ProjectNational Cancer Institute2005
Phase I Clinical Trials Of Novel AgentsNational Cancer Institute2003–2005
Nf-Kb Mediated Drug Resistance In Ovarian CancerNational Cancer Institute2000–2004
New Investigator Training In Drug DevelopmentNational Cancer Institute2000–2004
Core--PharmacologyNational Cancer Institute2001–2002
Core--BiostatisticsNational Cancer Institute2001–2002
Phase I Studies Of Anticancer AgentsNational Cancer Institute1998–2002
Developmental ChemotherapyNational Cancer Institute1996–2002
Ovarian Cancer--Clinical TrialsNational Cancer Institute1996–1997
Phase I Clinical Trials Of Anticancer AgentsNational Cancer Institute1995–1997
TNF Gene Regulation In Breast And Ovary CancerNational Cancer Institute1994–1997
Molecular Mechanisms Of Tumor Necrosis FactorNational Cancer Institute1990–1991
Molecular Mechanisms Of Tumor Necrosis Factor 1r01ca4772National Cancer Institute1989
Molecular Mechanisms Of Tumor Necrosis FactorNational Cancer Institute1989
Pharmacodynamics Of ARA-C Therapy In Human MalignancyNational Cancer Institute1988–1989
The Pharmacodynamics Of ARA-C In Human MalignancyNational Cancer Institute1985–1987